Cargando…

Real-world use of orphan medicinal products (OMPs) in rare disease (RD) patients: A population-based registry study

Background: Despite calls for the use of real-world data, the rare diseases (RD) treatment landscape suffers from a scarcity of data referred to orphan medicinal products (OMP) use at the population level. Objectives: We aim to describe the characteristics and patterns of utilization of OMP in a siz...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mazzucato, Monica, Minichiello, Cinzia, Vianello, Andrea, Visonà dalla Pozza, Laura, Toto, Ema, Facchin, Paola
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9563616/ https://www.ncbi.nlm.nih.gov/pubmed/36249759 http://dx.doi.org/10.3389/fphar.2022.940010

Ejemplares similares

Estimating mortality in rare diseases using a population-based registry, 2002 through 2019
por: Mazzucato, Monica, et al.
Publicado: (2023)

The Epidemiology of Transition into Adulthood of Rare Diseases Patients: Results from a Population-Based Registry
por: Mazzucato, Monica, et al.
Publicado: (2018)

A population-based registry as a source of health indicators for rare diseases: the ten-year experience of the Veneto Region’s rare diseases registry
por: Mazzucato, Monica, et al.
Publicado: (2014)

The Evolution of AIFA Registries to Support Managed Entry Agreements for Orphan Medicinal Products in Italy
por: Xoxi, Entela, et al.
Publicado: (2021)

Orphan drugs’ clinical uncertainty and prices: Addressing allocative and technical inefficiencies in orphan drug reimbursement
por: Eichler, Hans-Georg, et al.
Publicado: (2023)

The Guanine-Based Purinergic System: The Tale of An Orphan Neuromodulation
por: Di Liberto, Valentina, et al.
Publicado: (2016)

Comprehensive insights into the function and molecular and pharmacological regulation of neuron-derived orphan receptor 1, an orphan receptor
por: Hong, Hongxiang, et al.
Publicado: (2022)

Licensing of Orphan Medicinal Products—Use of Real-World Data and Other External Data on Efficacy Aspects in Marketing Authorization Applications Concluded at the European Medicines Agency Between 2019 and 2021
por: Naumann-Winter, Frauke, et al.
Publicado: (2022)

Advancements in therapeutically targeting orphan GPCRs
por: Stockert, Jennifer A., et al.
Publicado: (2015)

Editorial: Orphan GPCRs As Emerging Drug Targets
por: Fang, Ye, et al.
Publicado: (2015)

Orphan Drugs, Compounded Medication and Pharmaceutical Commons
por: Hendrickx, Kim, et al.
Publicado: (2021)

Real-World Effects of Chinese Herbal Medicine for Idiopathic Membranous Nephropathy (REACH-MN): Protocol of a Registry-Based Cohort Study
por: Yang, Lihong, et al.
Publicado: (2022)

The histamine H(4) receptor: from orphan to the clinic
por: Thurmond, Robin L.
Publicado: (2015)

Crowd Funding for Orphan Drugs: The Case of Baby Pia
por: Pinxten, Wim
Publicado: (2021)

Orphan Medicine Incentives: How to Address the Unmet Needs of Rare Disease Patients by Optimizing the European Orphan Medicinal Product Landscape Guiding Principles and Policy Proposals by the European Expert Group for Orphan Drug Incentives (OD Expert Group)
por: Aartsma-Rus, Annemieke, et al.
Publicado: (2021)

ORPHAcodes use for the coding of rare diseases: comparison of the accuracy and cross country comparability
por: Mazzucato, Monica, et al.
Publicado: (2023)

The therapeutic potential of orphan GPCRs, GPR35 and GPR55
por: Shore, Derek M., et al.
Publicado: (2015)

Reimbursement Status and Recommendations Related to Orphan Drugs in European Countries
por: Stawowczyk, Ewa, et al.
Publicado: (2019)

Orphan Drug Use in Patients With Rare Diseases: A Population-Based Cohort Study
por: Gorini, Francesca, et al.
Publicado: (2022)

Targeting Orphan Nuclear Receptors NR4As for Energy Homeostasis and Diabetes
por: Zhang, Chenyang, et al.
Publicado: (2020)

Reimbursement Legislations and Decision Making for Orphan Drugs in Central and Eastern European Countries
por: Malinowski, Krzysztof Piotr, et al.
Publicado: (2019)

Availability and Accessibility of Orphan Medicinal Products to Patients in Slovakia in the Years 2010–2019
por: Foltanova, Tatiana, et al.
Publicado: (2022)

How to Value Orphan Drugs? A Review of European Value Assessment Frameworks
por: Blonda, Alessandra, et al.
Publicado: (2021)

Better response to Tanreqing injection in frequent acute exacerbation of chronic obstructive pulmonary disease (AECOPD) patients—Real-world evidence from a nationwide registry (ACURE) study
por: Fan, Guohui, et al.
Publicado: (2023)

Real-world efficacy and safety of pyrotinib in patients with HER2-positive metastatic breast cancer: A prospective real-world study
por: Zhang, Qiongwen, et al.
Publicado: (2023)

Pharmacoepidemiology Research-Real-World Evidence for Decision Making
por: Bérard, Anick
Publicado: (2021)

Editorial: Real-world experience with CFTR modulator therapy
por: Tümmler, Burkhard, et al.
Publicado: (2023)

Methodological Quality Assessment of Budget Impact Analyses for Orphan Drugs: A Systematic Review
por: Abdallah, Khadidja, et al.
Publicado: (2021)

Long way to go: Progress of orphan drug accessibility in China from 2017 to 2022
por: Liu, Jia, et al.
Publicado: (2023)

The importance of helplines in National Plans
por: Mazzucato, Monica, et al.
Publicado: (2014)

Editorial: Big Data, Pharmacogenomics and Real-World Research in Pharmacology
por: Wei, James Cheng-Chung, et al.
Publicado: (2020)

Drug utilization research in Peru: Is real-world data available?
por: Rodríguez-Tanta, L. Yesenia, et al.
Publicado: (2023)

Trends in orphan drug use and spending among children and adolescents during 2010–2020 in Korea
por: Oh, Jung Yeon, et al.
Publicado: (2022)

Using real-world data for supporting regulatory decision making: Comparison of cardiovascular and safety outcomes of an empagliflozin randomized clinical trial versus real-world data
por: Jang, Ha Young, et al.
Publicado: (2022)

Piperlongumine is a ligand for the orphan nuclear receptor 4A1 (NR4A1)
por: Zhang, Lei, et al.
Publicado: (2023)

Real World Data in Health Technology Assessment of Complex Health Technologies
por: Hogervorst, Milou A., et al.
Publicado: (2022)

Registries for orphan drugs: generating evidence or marketing tools?
por: Hollak, Carla E. M., et al.
Publicado: (2020)

Assessing the feasibility of a web-based registry for multiple orphan lung diseases: the Australasian Registry Network for Orphan Lung Disease (ARNOLD) experience
por: Casamento, K., et al.
Publicado: (2016)

Editorial: The use of real world data for regulatory purposes in the rare diseases setting
por: Giannuzzi, Viviana, et al.
Publicado: (2022)

Direct Oral Anticoagulants: From Randomized Clinical Trials to Real-World Clinical Practice
por: Roberti, Roberta, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_cb1knecrc8r2j57alt192akjan